Food and Drug Administration (FDA) on the development program for BEMA
Buprenorphine/Naloxone, BDSI's potential treatment for opioid dependence.
We believe that BEMA
Buprenorphine has the potential to become a major player in the treatment of pain by addressing a significant unmet market need by virtue of a lower propensity for abuse and addiction compared to other opioids such as oxycodone and morphine.
A detailed summary of the proposed acquisition is set forth in the press release issued by Kinross and Bema
dated November 6, 2006 and in material change reports dated November 16, 2006 filed by Kinross and Bema
with securities regulatory authorities.
FDA on July 16, 2009, BEMA
Fentanyl is currently under regulatory review in the European Union with approval expected in 2010.
The acquisition will be completed by way of a shareholder-approved plan of arrangement whereby each Bema
common share will be exchanged for 0.
Andrew Finn, BDSI's Executive Vice President, Product Development added, "There is a tremendous opportunity for a product such as BEMA
Buprenorphine with a long duration of action and less potential for abuse and addiction compared to Schedule II opioids such as morphine and oxycodone.
VDM has a strong pedigree in representing metals and mining companies on the NYSE and is well-positioned to serve Bema
, one of the fastest growing gold producers in the world," said Robert Fagenson, CEO of VDM Specialists, LLC.
Placer Dome, Bema
and Arizona do not undertake to update any forward- looking statement that may be made from time to time by Placer Dome, Bema
or Arizona or on their behalf, except in accordance with applicable securities laws.
conducted an extensive exploration program at Julietta during 2002 consisting of diamond drilling, bulldozer trenching, geological mapping and geochemical sampling.
The Toronto Stock Exchanges neither approves nor disapproves the information contained in this News Release, Bema
Gold Corporation trades on The Toronto and American stock exchanges.
While our primary attention will continue to be on supporting all activities associated with the acceptance and approval of the NDA for BEMA
Fentanyl, we have now reached an important point where our pharmaceutical and clinical development activities for BEMA
Buprenorphine can accelerate," said Dr.
beneficially owns 11,230,714 Special Warrants which are exercisable into Shares and Warrants of EAGC.